And more. In back-to-back announcements, Eli Lilly said it will invest $200 million to expand its manufacturing site in Suzhou and will open its biotech incubator, known as Lilly Gateway Labs ...

Eli Lilly is expanding its innovation digs to Beijing ... jobs to the plant and brings Lilly’s total investment in the Suzhou site to nearly 15 billion Chinese yuan ($2.1 billion).

[Photo/Agencies] US pharmaceutical company Eli Lilly and Co recently announced a roughly $200 million expansion of its manufacturing site in Suzhou, Jiangsu province, that will enable it to ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly & Co. will set up a S$42 million ($31 million) digital health innovation hub in Singapore, expanding its research ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of tirzepatide. Weekly tirzepatide injections significantly ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Yet, Eli Lilly's GLP-1 medications are helping it compete with the leader. Plus, Lilly also has several other promising catalysts to consider. These are two of healthcare's biggest darlings right ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...